Literature DB >> 750115

Immunoglobulins in myasthenia gravis. Kinetic properties of the acetylcholine-receptor antibody studied during lymph drainage.

A K Lefvert.   

Abstract

A specific immunoglobulin, the receptor antibody, can be found in most patients with myasthenia gravis. In order to study the kinetic properties of this antibody, serial determinations of receptor antibody, total IgG and IgG 3 were made during drainage of thoracic duct lymph in three patients. The values obtained were used in a mathematical model to calculate some kinetic parameters. Values for T 1/2 and fractional rates of synthesis and catabolism obtained for total IgG and IgG 3 by this method were shown to agree with those found with other techniques. Most of the receptor antibody activity was found in the IgG 3 fraction but the receptor antibody had a shorter T 1/2 and higher fractional rates of synthesis and catabolism than IgG 3. These kinetic characteristics are consistent with rapid variations in plasma concentration of the receptor antibody. The cause of this rapid turnover could be strong antigenic stimuli and rapid elimination by the antigen, the cholinergic receptor protein.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 750115      PMCID: PMC1537462     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Clinical and experimental metabolism of normal 6.6s gamma-globulin in normal subjects and in patients with macroglobulinemia and multiple myeloma.

Authors:  A SOLOMON; T A WALDMANN; J L FAHEY
Journal:  J Lab Clin Med       Date:  1963-07

2.  Gamma-globulin and acquired immunity to human malaria.

Authors:  S COHEN; I A McGREGOR; S CARRINGTON
Journal:  Nature       Date:  1961-11-25       Impact factor: 49.962

3.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

4.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications.

Authors:  A K Lefvert; K Bergström; G Matell; P O Osterman; R Pirskanen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

7.  Antibodies against human cholinergic receptor proteins in patients with myasthenia gravis: Studies during immunosuppressive treatment. Preliminary report.

Authors:  A K Lefvert; G Matell
Journal:  Acta Med Scand       Date:  1977

8.  The mechanism of action of 17-hydroxy-11-dehydrocorticosterone (compound E) and of the adrenocorticotropic hormone in experimental hypersensitivity in rabbits.

Authors:  F G GERMUTH; J OYAMA; B OTTINGER
Journal:  J Exp Med       Date:  1951-08       Impact factor: 14.307

9.  Remission of myasthenia gravis following plasma-exchange.

Authors:  A J Pinching; D K Peters
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

10.  An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.

Authors:  J Lindstrom
Journal:  Clin Immunol Immunopathol       Date:  1977-01
View more
  3 in total

1.  The effect of extracorporeal antibody removal on antibody synthesis and catabolism in immunized rabbits.

Authors:  B Charlton; K Schindhelm
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

2.  Anti-acetylcholine receptor antibodies.

Authors:  A Vincent; J Newsom Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

Review 3.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.